Related Experiment Video

Updated: Mar 11, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

21.4K

[Antifungal medication: new substances, new experiences]

Dieter Buchheidt, Wolf-Karsten Hofmann

    Deutsche Medizinische Wochenschrift (1946)
    |December 1, 2016
    PubMed

    Insights

    Invasive fungal infections are increasing in vulnerable patients, with high mortality rates. This review details recent advances in antifungal treatment to improve patient outcomes.

    Area of Science:

    • Mycology
    • Infectious Diseases
    • Hematology

    Background:

    • Rising incidence of life-threatening invasive fungal infections (IFIs) in immunocompromised patients, including those with hematological malignancies, transplant recipients, ICU patients, and premature infants.
    • High mortality rates (up to 100%) for IFIs caused by Aspergillus species and mucormycetes, despite diagnostic and therapeutic advancements.
    • Need for comprehensive knowledge of diagnostic and treatment algorithms to improve patient prognosis.

    Purpose of the Study:

    • To review recent developments in the field of antifungal treatment for invasive fungal infections.
    • To provide essential knowledge on diagnostic and treatment algorithms for systemic fungal infections.

    Main Methods:

    • Literature review of recent advancements in antifungal treatment.
    • Synthesis of current diagnostic and therapeutic strategies for invasive fungal infections.

    Main Results:

    • Discussion of emerging antifungal therapies and treatment protocols.
    • Highlighting key strategies for managing invasive fungal infections.

    Conclusions:

    • Comprehensive understanding of antifungal treatment is crucial for improving outcomes in high-risk patient populations.
    • Continued research and updates in diagnostic and treatment algorithms are essential for combating invasive fungal infections.

    More Related Videos

    Quantifying the Antifungal Activity of Peptides Against Candida albicans06:45

    Quantifying the Antifungal Activity of Peptides Against Candida albicans

    Published on: January 13, 2023

    3.0K
    Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products06:47

    Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products

    Published on: December 5, 2020

    7.4K

    Related Concept Videos

    Fungal Phylum Microsporidia01:28

    Fungal Phylum Microsporidia

    Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
    662
    Combined Effects of Drugs: Synergism01:27

    Combined Effects of Drugs: Synergism

    Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
    Such synergistic combinations...
    7.1K
    Fungal Phylum Ascomycota01:28

    Fungal Phylum Ascomycota

    Phylum Ascomycota, a major division within the subkingdom Dikarya, comprises a diverse range of fungal species, including both unicellular yeasts and filamentous molds such as Aspergillus and Penicillium. These fungi thrive in a variety of habitats, from aquatic ecosystems to terrestrial environments, playing crucial ecological and economic roles.Morphology and ReproductionThe defining characteristic of Ascomycetes, commonly referred to as sac fungi, is the ascus—a sac-like structure that...
    2.0K
    Overview of Fungi01:29

    Overview of Fungi

    Fungi are a diverse group of eukaryotes more closely related to animals than other eukaryotes. Fungal cell walls comprise chitin, a polysaccharide that provides structural strength, and glucans, which contribute to flexibility and integrity. Other polysaccharides, such as mannans and galactosans, may supplement or replace chitin in some fungi. These adaptations, along with their preference for acidic environments and tolerance for high osmotic pressure, enable fungi to thrive in various...
    2.2K
    Antimicrobial Effectiveness01:28

    Antimicrobial Effectiveness

    The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
    1.6K
    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

    PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
    59